AlphaCentric Advisors LLC Invests $2.06 Million in Alphatec Holdings, Inc. (NASDAQ:ATEC)

AlphaCentric Advisors LLC bought a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 370,000 shares of the medical technology company’s stock, valued at approximately $2,057,000. Alphatec accounts for 1.5% of AlphaCentric Advisors LLC’s investment portfolio, making the stock its 18th largest holding. AlphaCentric Advisors LLC owned about 0.26% of Alphatec at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Net Worth Advisory Group acquired a new stake in shares of Alphatec during the third quarter worth about $76,000. Comerica Bank increased its position in Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after purchasing an additional 2,534 shares during the period. Van ECK Associates Corp increased its position in Alphatec by 57.0% during the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after purchasing an additional 6,998 shares during the period. Tempus Wealth Planning LLC acquired a new position in Alphatec during the 3rd quarter worth approximately $107,000. Finally, Stephens Inc. AR boosted its stake in shares of Alphatec by 51.4% during the 3rd quarter. Stephens Inc. AR now owns 21,743 shares of the medical technology company’s stock worth $121,000 after acquiring an additional 7,382 shares in the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alphatec

In other Alphatec news, Director David M. Demski purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were bought at an average price of $5.67 per share, with a total value of $283,500.00. Following the completion of the acquisition, the director now owns 288,441 shares in the company, valued at approximately $1,635,460.47. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and set a $13.00 price objective on shares of Alphatec in a report on Thursday, October 31st. Wells Fargo & Company dropped their price objective on Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Stifel Nicolaus cut their price objective on Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Finally, Morgan Stanley lowered Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Alphatec Stock Up 3.1 %

Shares of ATEC stock opened at $8.36 on Tuesday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business has a 50 day moving average of $5.87 and a two-hundred day moving average of $8.56. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $17.34.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.